Logo image of HZNP

HORIZON THERAPEUTICS PLC (HZNP) Stock Fundamental Analysis

NASDAQ:HZNP - Nasdaq - IE00BQPVQZ61 - Common Stock - Currency: USD

116.3  +0.05 (+0.04%)

After market: 116.34 +0.04 (+0.03%)

Fundamental Rating

6

HZNP gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. HZNP gets an excellent profitability rating and is at the same time showing great financial health properties. HZNP has a correct valuation and a medium growth rate. With these ratings, HZNP could be worth investigating further for quality investing!.


Dividend Valuation Growth Profitability Health

Quickly go to:

8

1. Profitability

1.1 Basic Checks

HZNP had positive earnings in the past year.
In the past year HZNP had a positive cash flow from operations.
HZNP had positive earnings in 4 of the past 5 years.
Each year in the past 5 years HZNP had a positive operating cash flow.
HZNP Yearly Net Income VS EBIT VS OCF VS FCFHZNP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 500M 1B

1.2 Ratios

HZNP has a Return On Assets of 4.71%. This is amongst the best in the industry. HZNP outperforms 95.21% of its industry peers.
Looking at the Return On Equity, with a value of 8.25%, HZNP belongs to the top of the industry, outperforming 95.38% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 5.35%, HZNP belongs to the top of the industry, outperforming 95.87% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for HZNP is significantly below the industry average of 14.04%.
Industry RankSector Rank
ROA 4.71%
ROE 8.25%
ROIC 5.35%
ROA(3y)6.1%
ROA(5y)6.05%
ROE(3y)10.47%
ROE(5y)10.88%
ROIC(3y)6.68%
ROIC(5y)4.8%
HZNP Yearly ROA, ROE, ROICHZNP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 20 -20

1.3 Margins

HZNP has a Profit Margin of 12.02%. This is amongst the best in the industry. HZNP outperforms 96.04% of its industry peers.
In the last couple of years the Profit Margin of HZNP has declined.
HZNP has a Operating Margin of 15.58%. This is amongst the best in the industry. HZNP outperforms 96.53% of its industry peers.
HZNP's Operating Margin has improved in the last couple of years.
HZNP has a Gross Margin of 75.21%. This is amongst the best in the industry. HZNP outperforms 84.49% of its industry peers.
In the last couple of years the Gross Margin of HZNP has grown nicely.
Industry RankSector Rank
OM 15.58%
PM (TTM) 12.02%
GM 75.21%
OM growth 3Y23.86%
OM growth 5YN/A
PM growth 3Y-31.18%
PM growth 5YN/A
GM growth 3Y1.14%
GM growth 5Y6.97%
HZNP Yearly Profit, Operating, Gross MarginsHZNP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 20 -20 40 60

More info and screens

7

2. Health

2.1 Basic Checks

HZNP has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for HZNP remains at a similar level compared to 1 year ago.
The debt/assets ratio for HZNP has been reduced compared to a year ago.
HZNP Yearly Shares OutstandingHZNP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M 200M
HZNP Yearly Total Debt VS Total AssetsHZNP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2B 4B 6B 8B

2.2 Solvency

HZNP has an Altman-Z score of 5.10. This indicates that HZNP is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 5.10, HZNP belongs to the top of the industry, outperforming 81.35% of the companies in the same industry.
The Debt to FCF ratio of HZNP is 2.67, which is a good value as it means it would take HZNP, 2.67 years of fcf income to pay off all of its debts.
HZNP's Debt to FCF ratio of 2.67 is amongst the best of the industry. HZNP outperforms 95.54% of its industry peers.
HZNP has a Debt/Equity ratio of 0.48. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of HZNP (0.48) is worse than 74.92% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.48
Debt/FCF 2.67
Altman-Z 5.1
ROIC/WACC0.75
WACC7.16%
HZNP Yearly LT Debt VS Equity VS FCFHZNP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 1B 2B 3B 4B 5B

2.3 Liquidity

HZNP has a Current Ratio of 4.27. This indicates that HZNP is financially healthy and has no problem in meeting its short term obligations.
HZNP's Current ratio of 4.27 is in line compared to the rest of the industry. HZNP outperforms 41.58% of its industry peers.
A Quick Ratio of 4.09 indicates that HZNP has no problem at all paying its short term obligations.
HZNP has a Quick ratio (4.09) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.27
Quick Ratio 4.09
HZNP Yearly Current Assets VS Current LiabilitesHZNP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 1B 2B 3B

More info and screens

6

3. Growth

3.1 Past

The earnings per share for HZNP have decreased strongly by -19.39% in the last year.
The Earnings Per Share has been growing by 33.01% on average over the past years. This is a very strong growth
Looking at the last year, HZNP shows a decrease in Revenue. The Revenue has decreased by -4.42% in the last year.
HZNP shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 28.00% yearly.
EPS 1Y (TTM)-19.39%
EPS 3Y34.76%
EPS 5Y33.01%
EPS Q2Q%12.15%
Revenue 1Y (TTM)-4.42%
Revenue growth 3Y40.8%
Revenue growth 5Y28%
Sales Q2Q%7.82%

3.2 Future

Based on estimates for the next years, HZNP will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.92% on average per year.
HZNP is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.94% yearly.
EPS Next Y-5.01%
EPS Next 2Y8.89%
EPS Next 3Y11.9%
EPS Next 5Y15.92%
Revenue Next Year5.55%
Revenue Next 2Y9.53%
Revenue Next 3Y10.34%
Revenue Next 5Y9.94%

3.3 Evolution

Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
HZNP Yearly Revenue VS EstimatesHZNP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2B 4B 6B
HZNP Yearly EPS VS EstimatesHZNP Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 5 10

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 25.90, HZNP can be considered very expensive at the moment.
Based on the Price/Earnings ratio, HZNP is valued cheaper than 95.54% of the companies in the same industry.
HZNP's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 29.63.
The Price/Forward Earnings ratio is 20.14, which indicates a rather expensive current valuation of HZNP.
96.53% of the companies in the same industry are more expensive than HZNP, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of HZNP to the average of the S&P500 Index (22.68), we can say HZNP is valued inline with the index average.
Industry RankSector Rank
PE 25.9
Fwd PE 20.14
HZNP Price Earnings VS Forward Price EarningsHZNP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

HZNP's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. HZNP is cheaper than 94.88% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, HZNP is valued cheaply inside the industry as 96.37% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 27.79
EV/EBITDA 27.94
HZNP Per share dataHZNP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15 20

4.3 Compensation for Growth

The excellent profitability rating of HZNP may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.78
EPS Next 2Y8.89%
EPS Next 3Y11.9%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for HZNP!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HORIZON THERAPEUTICS PLC

NASDAQ:HZNP (10/5/2023, 8:25:26 PM)

After market: 116.34 +0.04 (+0.03%)

116.3

+0.05 (+0.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-08 2023-08-08/bmo
Earnings (Next)N/A N/A
Inst Owners0%
Inst Owner Change0%
Ins Owners0.58%
Ins Owner Change0%
Market Cap26.63B
Analysts50.91
Price Target118.83 (2.18%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-6.7%
Min EPS beat(2)-27.35%
Max EPS beat(2)13.95%
EPS beat(4)3
Avg EPS beat(4)4.23%
Min EPS beat(4)-27.35%
Max EPS beat(4)21.5%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-1.41%
Min Revenue beat(2)-9.59%
Max Revenue beat(2)6.77%
Revenue beat(4)3
Avg Revenue beat(4)-0.15%
Min Revenue beat(4)-9.59%
Max Revenue beat(4)6.77%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-14.76%
EPS NY rev (1m)0%
EPS NY rev (3m)-17.11%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-4.34%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-4.27%
Valuation
Industry RankSector Rank
PE 25.9
Fwd PE 20.14
P/S 7.31
P/FCF 27.79
P/OCF 25.59
P/B 5.01
P/tB 26.53
EV/EBITDA 27.94
EPS(TTM)4.49
EY3.86%
EPS(NY)5.77
Fwd EY4.97%
FCF(TTM)4.19
FCFY3.6%
OCF(TTM)4.54
OCFY3.91%
SpS15.92
BVpS23.19
TBVpS4.38
PEG (NY)N/A
PEG (5Y)0.78
Profitability
Industry RankSector Rank
ROA 4.71%
ROE 8.25%
ROCE 6.77%
ROIC 5.35%
ROICexc 7.58%
ROICexgc 27.86%
OM 15.58%
PM (TTM) 12.02%
GM 75.21%
FCFM 26.3%
ROA(3y)6.1%
ROA(5y)6.05%
ROE(3y)10.47%
ROE(5y)10.88%
ROIC(3y)6.68%
ROIC(5y)4.8%
ROICexc(3y)9.75%
ROICexc(5y)6.96%
ROICexgc(3y)39.54%
ROICexgc(5y)N/A
ROCE(3y)8.46%
ROCE(5y)6.07%
ROICexcg growth 3Y27.62%
ROICexcg growth 5YN/A
ROICexc growth 3Y33.99%
ROICexc growth 5YN/A
OM growth 3Y23.86%
OM growth 5YN/A
PM growth 3Y-31.18%
PM growth 5YN/A
GM growth 3Y1.14%
GM growth 5Y6.97%
F-Score6
Asset Turnover0.39
Health
Industry RankSector Rank
Debt/Equity 0.48
Debt/FCF 2.67
Debt/EBITDA 2.66
Cap/Depr 21.15%
Cap/Sales 2.26%
Interest Coverage 4.07
Cash Conversion 108.78%
Profit Quality 218.81%
Current Ratio 4.27
Quick Ratio 4.09
Altman-Z 5.1
F-Score6
WACC7.16%
ROIC/WACC0.75
Cap/Depr(3y)32.95%
Cap/Depr(5y)21.63%
Cap/Sales(3y)3.95%
Cap/Sales(5y)2.73%
Profit Quality(3y)169.09%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-19.39%
EPS 3Y34.76%
EPS 5Y33.01%
EPS Q2Q%12.15%
EPS Next Y-5.01%
EPS Next 2Y8.89%
EPS Next 3Y11.9%
EPS Next 5Y15.92%
Revenue 1Y (TTM)-4.42%
Revenue growth 3Y40.8%
Revenue growth 5Y28%
Sales Q2Q%7.82%
Revenue Next Year5.55%
Revenue Next 2Y9.53%
Revenue Next 3Y10.34%
Revenue Next 5Y9.94%
EBIT growth 1Y-37.19%
EBIT growth 3Y74.4%
EBIT growth 5YN/A
EBIT Next Year6.03%
EBIT Next 3Y14.62%
EBIT Next 5Y17.3%
FCF growth 1Y83.52%
FCF growth 3Y42.98%
FCF growth 5Y33.65%
OCF growth 1Y72.19%
OCF growth 3Y43.43%
OCF growth 5Y34.64%